title: Inclusion of patients with brain metastases in phase I trials: an unmet need.
abstract: Patients with brain metastases are increasing in number; however, these patients are often excluded in phase I/II trials due to perceived poor prognosis, risk of hemorrhage, inefficient drug delivery, and confounding toxicities. Tsimberidou and colleagues demonstrate that selected patients can be appropriately enrolled in phase I trials and have outcomes representative of the general cancer population.
authors.affiliation: Developmental Therapeutics Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
authors.forename: Mrinal M
authors.initials: MM
authors.lastname: Gounder
authors.forename: David R
authors.initials: DR
authors.lastname: Spriggs
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000556:secondary* / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D000970:Antineoplastic Agents